Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers
1.7.2022 15:35:00 EEST | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing.
Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and security capabilities to optimize service experience, all while enabling service providers to sustain profitable business growth.
Juniper’s new Cloud Metro systems uniquely feature industry-leading energy-efficient, adaptive power designs as their foundational principle, enabling unused features and Packet Forwarding Engines (PFEs) to be automatically switched off when not in use. The removable modular power shelf design reduces e-waste and extends system lifetimes by accommodating up to 48 times bandwidth growth within the same chassis. It is certified as Titanium grade by CLEAResult® in its 80 Plus program, the first and only metro networking device power module to accomplish such a rating.
The future-proofed scale, capacity, performance and smart features of Juniper’s Cloud Metro portfolio replace the traditional 3-5 year ‘rip-and-replace’ network lifecycles with 7-12 year lifecycles. Pay-as-you-go models and a breadth of interface options allow service providers to flex their investment economically in line with demand.
Juniper’s advanced use of AI and cloud-delivered automation equips service providers to simplify day-to-day workflows, deploy services faster (with device onboarding taking just minutes instead of hours), reduce trouble tickets and accelerate time-to-service (and therefore revenue) restoration. This significantly improves productivity, empowering network engineers and operators to accomplish more, which is critical for employee satisfaction and retention.
The new solutions also deliver up to 71 percent lower Total Cost of Ownership (TCO) by leveraging the latest generation of silicon, industry-leading system design and AI-enabled Device Onboarding-as-a-Service. Zero Trust security is built-in rather than bolted-on, while active service assurance is embedded to deliver proactive service testing, monitoring and remediation.
Solution News Overview:
- Juniper Paragon™ Automation as a Service¹ is the industry’s only AI-enabled, cloud-delivered automation portfolio for metro networks, delivering immediate time-to-service value from months to minutes and reduced Mean Time to Know (MTTK) and Mean Time to Recovery (MTTR).
- Juniper AI-Enabled Device Onboarding-as-a-Service is the first-use case to be launched leveraging Juniper Paragon Automation as a Service, driving real business outcomes by significantly reducing device onboarding times.
- Juniper Networks™ ACX7000 Family² products are sustainable, high-performance systems leveraging unique design and adaptive power innovations that deliver up to 77 percent lower power consumption, up to 64 percent better space efficiencies and 4-7 years longer system lifetime than leading competitive products available today. The portfolio also delivers the industry’s fastest router line card, highest 400GE density and fabric capacity per slot, up to 21.6 Tbps with 54x400GE ports, ready for 800G and beyond.
- Juniper Paragon Active Assurance³ test agents are embedded in JUNOS® OS Evolved, available in all ACX7000 models. This turns the cloud metro network into a distributed sensor for assuring user experience proactively which removes the need for additional, standalone probe hardware to be deployed. Additionally, with the new capability of emulating 5G UE/gNB, service providers can now simulate traffic for both the control plane and user plane, ensuring each 5G network slice meets expected SLA.
- Zero Trust Security ⁴ principles and the threat detection, analysis and prevention fundamentals of Juniper’s Connected Security portfolio have been applied throughout the Juniper Cloud Metro solution. Unique cryptographic digital identities are implemented with the Trusted Platform Module (TPM 2.0) across the Cloud Metro IP services fabric, enabling device attestation and RFC-compliant secure zero-touch provisioning (sZTP). In addition, file encryption and MACsec are implemented to protect data at rest and data in transit. This holistic approach to trust is further enhanced by Paragon’s ability to automatically validate the security deployment and operation across a network of ACX7000 devices.
- Juniper Networks 400G ZR/ZR+ optics ⁵ co-developed to reduce service provider costs by consolidating IP and optical layers with coherent pluggable optics, which eliminates an entire layer of DWDM transponder terminals by integrating 400G ZR/ZR+ Digital Coherent Optics (DCO). These optics fully comply with industry specifications from OpenZR+ and OIF.
Supporting Quotes
“In a world of 'retro metros,' Juniper’s new Cloud Metro solution stands apart. Our cloud-delivered Paragon Automation-as-a-Service promises immediate productivity increases for service providers. Instead of building complex, time-consuming 'DIY' automation solutions, they are empowered to focus on assuring service experiences for their customers. By extending our proven AI solution to the service provider WAN, we can improve productivity for customer operations teams by dramatically reducing trouble tickets and increasing network availability. And our extended ACX7000 Family delivers the most secure, assured, scalable and intelligent Cloud Metro portfolio on the market. This is the answer to service provider needs for a sustainable future for their profits, their people and the planet.”
- Brendan Gibbs, Senior Vice President of Automated WAN Solutions, Juniper Networks
“Digital transformation is moving into its next phase which is all about transforming operational technology (OT) and driving the distributed delivery of new applications and use cases based on emerging technologies such as AI and AR. The metro edge is key to supporting the massive data, real-time performance and sustainability demands that this new era of OT transformation is bringing. This important industry shift requires the re-imagining and re-engineering of the metro network and Juniper is showing leadership here in its Cloud Metro portfolio. Service providers that want to deliver reliable, secure and high-performing services at the metro edge with a sustainable business model should pay close attention.”
- Caroline Chappell, Research Director, Cloud Practice, Analysys Mason
“Our metro connectivity services across more than 260 major cities around the world meet our customers’ need for secure, scalable and high-performance networking. We experience continuous demand for secure connectivity and expect to see double-digit traffic growth on our network, as we continue to provide the great experience our customers require. We’re long-term supporters of Juniper’s vision for high-performance, scalable IP networking and are excited to see the significant enhancements and innovation featured in their Cloud Metro portfolio that can bring more benefits for our customers in the future.”
- Don MacNeil, Chief Operating Officer, GTT Communications
“We are excited that the partnership between Broadcom and Juniper has delivered such a comprehensive portfolio of WAN routing platforms, all based on our leading Jericho and Qumran silicon. This announcement is especially compelling as it showcases Broadcom’s Jericho 2c+ silicon enabling a 50 percent increase to the industry’s highest-density 400G routing line card in a modular chassis. With market-leading 54 ports of 400G per slot at 21.6Tbps, this performance underscores the unmatched scalability and power efficiency of the product offering. We are thankful for our engineering teams.”
- Ram Velaga, Senior Vice President and General Manager, Core Switching Group, Broadcom
Solution Availability
¹AI-enabled Paragon Automation-as-a-Service – available 1H23
²ACX7000 Family:
- ACX7100-32C, ACX7100-48L, ACX7509 – available now
- ACX7024 – orderable now, available Q3’22
- ACX7908, ACX7348 – orderable 1H’23
³Juniper embedded Paragon Active Assurance – available 2H’22
⁴ Built-in zero trust security with SaaS-based network trust attestation – available 1H’23
⁵Juniper 400G ZR/ZR+ optics – orderable & available Q3’22
Additional Resources
Cloud Metro Solution Page
Blog: Cloud Metro: Reimagining Metro Networks for Sustainable Business Growth
Blog: Welcome to the Future of Network Automation: Juniper Paragon Automation-as-a-Service
Blog: Reimagining Metro Architectures for the Experience-First Era
Blog: Balancing Design Choices for Sustainable Growth: Juniper ACX7000 Family
ACX7000 Family Datasheet
Solution Brief: Juniper Cloud Metro as the Experience Sensor
Solution Brief: AI-Enabled Device Onboarding as a Service
Demo: Paragon Automation as a Service Device Onboarding
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Statement of Product Direction
The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.
Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.
category-serviceprovider
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005027/en/
Contact information
Media Relations:
Penny Still
Juniper Networks
+44 (0) 1372 385 692
pstill@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
